Predicting Progression to Mild Cognitive Impairment

Authors

Ronald C. Petersen, Mayo Clinic
Emily S. Lundt, Mayo Clinic
Terry M. Therneau, Mayo Clinic
Stephen D. Weigand, Mayo Clinic
David S. Knopman, Mayo Clinic
Michelle M. Mielke, Mayo Clinic
Rosebud O. Roberts, Mayo Clinic
Val J. Lowe, Mayo Clinic
Mary M. Machulda, Mayo Clinic
Walter K. Kremers, Mayo Clinic
Yonas E. Geda, Mayo Clinic Scottsdale-Phoenix, ArizonaFollow
Clifford R. Jack, Mayo Clinic

Document Type

Article

Abstract

© 2018 American Neurological Association Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

Publication Date

1-1-2019

Publication Title

Annals of Neurology

ISSN

03645134

Volume

85

Issue

1

First Page

155

Last Page

160

PubMed ID

30521086

Digital Object Identifier (DOI)

10.1002/ana.25388

Recommended Citation

Petersen, Ronald C.; Lundt, Emily S.; Therneau, Terry M.; Weigand, Stephen D.; Knopman, David S.; Mielke, Michelle M.; Roberts, Rosebud O.; Lowe, Val J.; Machulda, Mary M.; Kremers, Walter K.; Geda, Yonas E.; and Jack, Clifford R., "Predicting Progression to Mild Cognitive Impairment" (2019). Neurology. 347.
https://scholar.barrowneuro.org/neurology/347